[wplist title=”Elon Musk turns a drug name typo into a sharp jab at weight-loss drug culture, blending pharma critique with his trademark snark.” link=”https://x.com/elonmusk/status/2057767989366124725″ img=”https://www.elonmuskfeed.com/wp-content/uploads/2026/05/musk2.jpg” price=”May 22, 2026″ oprice=”❤️ 183 Likes” btn=”View on X” ]RT @elonmusk: @tunguz I know it’s wrong, but I keep reading the name of the drug as Retardatide and thinking ok you lose a few iq points, b…[/wplist]
💡 Inside Track & Deep Insight
Elon Musk’s tweet, retweeting @tunguz’s observation about misreading ‘retatrutide’ as ‘retardatide,’ is more than a simple joke. It subtly nods to the ongoing controversy around GLP-1 agonist drugs like Ozempic and Wegovy, which have exploded in popularity for weight loss but also carry side effects including cognitive fogginess. By linking the drug to IQ loss, Musk leans into cultural anxieties about quick-fix medications vs. lifestyle discipline. The wordplay also reflects Musk’s broader tendency to use humor to comment on biotech trends, a domain where he’s invested via Neuralink. While this is a lighthearted meme, it could influence retail sentiment on weight-loss drug stocks like Novo Nordisk (NVO) in the short term, especially as Musk’s Twitter/X platform amplifies discourse. No crypto or space angle here—purely cultural commentary.
发表回复